The rising number of medicine recalls is a key stumbling block to the market's expansion. Manufacturers of tuberculosis drugs market face obstacles such as an increase in product recalls due to packaging or manufacturing defects. In India, for example, Sandoz recalled a batch of tuberculosis (TB) medications due to improper packaging. Furthermore, the Philippines Food and Medicine Administration recalled Novartis' drug Onecure in 2016 due to an insufficient amount of rifampicin in the drug.
Another element limiting the market's growth is the high cost of medications. Second-line therapy medications are more expensive than first-line treatment drugs, and they have more side effects and high levels of toxicity.
Read More:
https://bloggerstrive.blogspot.com/2022/03/tuberculosis-drugs-market-overview.html
Click here for Tuberculosis Drugs Market Report:
https://www.coherentmarketinsights.com/market-insight/tuberculosis-drugs-market-191
Click here for Tuberculosis Drugs Market Press Release:
